Inotrem
Latest round
- Series B
Last raised
- Apr 2020
Total raised
- $38M
Investors
- 7
About Inotrem
Inotrem SA, founded in 2013 and headquartered in Paris, France, specializes in immunotherapy aimed at treating severe inflammatory diseases.000 mn.Inotrem specializes in developing immunotherapy solutions that focus on the TREM-1 pathway, crucial for managing inflammatory responses. Its lead product, nangibotide, is in late-stage clinical development for acute inflammatory diseases like septic shock and COVID-19.S.9 mn for the year 2019.S. and Europe with its innovative treatments and anticipates launching INO-02 in the coming years.
Who invested in Inotrem
7 investors across 3 rounds
See all investors in Inotrem
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Inotrem
Who invested in Inotrem?
Inotrem has 7 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Inotrem raised?
Inotrem has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Inotrem last raise money?
Inotrem's most recent round on record is a Series B, in Apr 2020.
What does Inotrem do?
Inotrem SA, founded in 2013 and headquartered in Paris, France, specializes in immunotherapy aimed at treating severe inflammatory diseases.
Where is Inotrem headquartered?
Inotrem is headquartered in Paris, France.
Which VCs invest in companies like Inotrem?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Generation Investment Management back biotechnology companies at Inotrem's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Inotrem? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.